Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.

The American journal of psychiatry - 1 May 2024

Morley Kirsten C, Kranzler Henry R, Luquin Natasha, Jamshidi Nazila, Adams Claire, Montebello Mark, Tremonti Chris, Dali Gezelle, Logge Warren, Baillie Andrew, Teesson Maree, Trent Ronald, Haber Paul S

Abstract excerpt

OBJECTIVE: There have been no well-controlled and well-powered comparative trials of topiramate with other pharmacotherapies for alcohol use disorder (AUD), such as naltrexone. Moreover, the literature is mixed on the effects of two polymorphisms-rs2832407 (in GRIK1) and rs1799971 (in OPRM1)-on response to topiramate and naltrexone, respectively. The authors sought to examine the comparative effectiveness of...

Read the complete abstract on PubMed

Topics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share this publication in a Topic to start or enrich a Post.

Share to Alcoholism
Share to Double-Blind Method
Share to Fructose
Share to Naltrexone
Share to Narcotic Antagonists
Share to Receptors, Kainic Acid
Share to Receptors, Opioid, mu
Share to Treatment Outcome

Source

Identifiers

PMID: 38706338
DOI: 10.1176/appi.ajp.20230666

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.PMID 38706338Read ↗

An intensive longitudinal examination of topiramate treatment for alcohol use disorder: a secondary analysis of data from a randomized controlled trial.Semantic proximity Read ↗

Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism.Semantic proximity Read ↗

Posttreatment effects of topiramate treatment for heavy drinking.Semantic proximity Read ↗

Combined analysis of the moderating effect of a GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder.Semantic proximity Read ↗

A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers.Semantic proximity Read ↗

GRIK1 genotype moderates topiramate's effects on daily drinking level, expectations of alcohol's positive effects and desire to drink.Semantic proximity Read ↗

Topiramate's reduction of body mass index in heavy drinkers: lack of moderation by a GRIK1 polymorphism.Semantic proximity Read ↗

Balancing risk and benefit in heavy drinkers treated with topiramate: implications for personalized care.Semantic proximity Read ↗

Pharmacotherapy for alcohol dependence: A stratified approach.Semantic proximity Read ↗

Pharmacogenetics of alcohol and alcohol dependence treatment.Semantic proximity Read ↗

Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.Semantic proximity Read ↗

Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.